School of Pharmaceutical Sciences , Sun Yat-Sen University , Guangzhou 510006 , China.
School of Pharmaceutical Sciences , Shenzhen University Health Science Center , Shenzhen 518060 , China.
J Med Chem. 2018 Mar 22;61(6):2447-2459. doi: 10.1021/acs.jmedchem.7b01697. Epub 2018 Mar 1.
Downregulating transcription of the oncogene c-MYC is a feasible strategy for cancer therapy. Stabilization of the G-quadruplex structure present in the c-MYC promoter can suppress c-MYC transcription. Thus, far, several ligands targeting this structure have been developed. However, most have shown no selectivity for the c-MYC G-quadruplex over other G-quadruplexes, leading to uncertain side effects. In this study, through structural modification of aryl-substituted imidazole/carbazole conjugates, a brand-new, four-leaf clover-like ligand called IZCZ-3 was found to preferentially bind and stabilize the c-MYC G-quadruplex. Further intracellular studies indicated that IZCZ-3 provoked cell cycle arrest and apoptosis and thus inhibited cell growth, primarily by blocking c-MYC transcription through specific targeting of the promoter G-quadruplex structure. Notably, IZCZ-3 effectively suppressed tumor growth in a mouse xenograft model. Accordingly, this work provides an encouraging example of a selective small molecule that can target one particular G-quadruplex structure, and the selective ligand might serve as an excellent anticancer agent.
下调癌基因 c-MYC 的转录是癌症治疗的一种可行策略。稳定 c-MYC 启动子中存在的 G-四链体结构可以抑制 c-MYC 转录。迄今为止,已经开发了几种针对该结构的配体。然而,大多数配体对 c-MYC G-四链体的选择性都不如其他 G-四链体,导致不确定的副作用。在这项研究中,通过对芳基取代的咪唑/咔唑化合物进行结构修饰,发现了一种全新的四叶苜蓿样配体,称为 IZCZ-3,它可以优先结合并稳定 c-MYC G-四链体。进一步的细胞内研究表明,IZCZ-3 通过特异性靶向启动子 G-四链体结构,引发细胞周期停滞和细胞凋亡,从而抑制细胞生长,主要是通过阻断 c-MYC 转录。值得注意的是,IZCZ-3 有效地抑制了小鼠异种移植模型中的肿瘤生长。因此,这项工作为可以靶向特定 G-四链体结构的选择性小分子提供了一个令人鼓舞的范例,该选择性配体可能成为一种优秀的抗癌药物。